CHECKLIST AND RISK STRATIFICATION FOR OPENING OF INTERVENTIONAL PAIN MANAGEMENT PRACTICES
On April 27, we sent you a toolkit explaining morbidity risk mitigation flowchart for IPM and ASIPP risk stratification of patients presenting for pain procedures. This toolkit is for Phase I only.
Since releasing it, we have received multiple comments. There have been a few comments and requests for changes. In response, we have taken another look at it and made the appropriate changes. Please look over each document.
As we mentioned before, ASIPP Task Force Committee with Shalini, Sudhir, Amol, Chris, and Kartic worked extremely hard in arriving at this document, spending countless hours in the preparation of them.
Since then, we have also received comments from member of various states explaining that they can either do the testing on all patients or follow the association guidelines, so this will be a great opportunity for you to use them in your state. If the State Department of Health guidelines are too harsh, we can send them an explanatory letter.
It seems that there is some misunderstanding in reference to the scoring. In the low-risk category, some may get no scores. Consequently, it won’t be eight (8) for everyone. Some may be scored as zero (0) if they don’t have any positives with age, BMI, A1C of 6.5, and blood glucose levels of 120 between 5.7 and 6.4, whereas other factors are none. Consequently a patient may be zero (0) if they don’t meet any of these risk factors, or at the most a three (3), if they are all low-risk factors.
Please replace this document and use the new one to avoid the confusion: ASIPP Risk Stratification of Patients Presenting for Pain Procedures: Deceasing Morbidity of COVID-19
For your convenience, we are providing all of the documents once again:
ASIPP COVID-19 Morbidity Risk Mitigation Flow Chart for IPM
Patient Consent for Pain Management Procedures During the COVID-19 Pandemic
FAQs Regarding Return to Practice
If you have any further questions, please feel free to contact the undersigned: [email protected] or Melinda Martin at [email protected]. Please do not contact the authors directly.
